X Square Capital LLC Grows Position in Hims & Hers Health, Inc. $HIMS

X Square Capital LLC lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 53.3% during the second quarter, HoldingsChannel reports. The firm owned 235,290 shares of the company’s stock after purchasing an additional 81,810 shares during the quarter. Hims & Hers Health accounts for about 4.2% of X Square Capital LLC’s investment portfolio, making the stock its biggest holding. X Square Capital LLC’s holdings in Hims & Hers Health were worth $11,729,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health in the 2nd quarter worth about $29,000. Bessemer Group Inc. boosted its stake in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the first quarter worth approximately $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health during the 1st quarter valued at $41,000. Finally, Larson Financial Group LLC raised its holdings in Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after buying an additional 458 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Truist Financial decreased their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Weiss Ratings restated a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a report on Friday, September 12th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $38.92.

Insider Activity

In related news, CFO Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock in a transaction on Friday, October 17th. The stock was sold at an average price of $57.13, for a total value of $662,250.96. Following the completion of the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,637 shares of Hims & Hers Health stock in a transaction on Monday, October 27th. The shares were sold at an average price of $50.10, for a total value of $132,113.70. Following the completion of the transaction, the insider owned 158,493 shares of the company’s stock, valued at approximately $7,940,499.30. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 1,432,271 shares of company stock valued at $74,229,585. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Trading Up 3.4%

Shares of NYSE HIMS opened at $45.55 on Monday. Hims & Hers Health, Inc. has a twelve month low of $18.33 and a twelve month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock has a fifty day simple moving average of $51.39 and a 200-day simple moving average of $50.61. The stock has a market capitalization of $10.30 billion, a PE ratio of 56.94, a PEG ratio of 3.15 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same period in the previous year, the firm posted $0.06 earnings per share. The company’s quarterly revenue was up 72.6% compared to the same quarter last year. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.